Shots:

• The BLA filling is in response to the Breakthrough Therapy designation granted in 2016 to V920- taken alone or in combination to treat serious or life-threatening disease or condition
• In 2014- Merck gained rights for V920 from NewLink Genetics Corporation which was initially developed by Public Health Agency of Canada’s National Microbiology Laboratory
• V920 is an Ebola Vaccine currently evaluated in P-III. The BLA submission is expected to complete in 2019

Ref: Merck | Image: Merck